Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy

Clinical Therapeutics

Volumn 29, Issue 2, 2007, Pages 334-341

  Makus, Ken G ^a   McCormick, John ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b McKesson Phase 4 Solutions   (Canada)

Author keywords

epilepsy; generic; lamotrigine; substitution

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; GENERIC DRUG; LAMOTRIGINE; PHENYTOIN; TOPIRAMATE; VALPROATE SEMISODIUM;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGITATION; ANXIETY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG FORMULATION; DRUG SUBSTITUTION; EPILEPSY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MENTAL DEFICIENCY; MOOD DISORDER; MYELIN DEFICIENCY; PHYSICAL DISABILITY; PRESCRIPTION; RETT SYNDROME; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICONVULSANTS; CANADA; CHILD; CHILD, PRESCHOOL; DRUGS, GENERIC; EPILEPSY; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MEDICAL RECORDS; MIDDLE AGED; PHARMACISTS; PHYSICIANS; RETROSPECTIVE STUDIES; SEIZURES; THERAPEUTIC EQUIVALENCY; TRIAZINES;

EID: 34247509372     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.02.005     Document Type: Article

References (15)

1. European white paper on epilepsy. Epilepsia 44 Suppl 6 (2003) 1-88
2. Crawford P., Freely M., Guberman A., and Krarner G. Are there potential problems with generic substitution anti-epileptic dmgs? A review of issues. Seizure 15 (2006) 165-176
3. Crawford P., and Hall W.W. Chappell. Generic prescribing for epilepsy. Is it safe?. Seizure 5 (1996) 1-5
4. Besag F.M. Is generic prescribing acceptable in epilepsy?. Drug Saf 23 (2000) 173-182
5. Gubemnan A., and Corman C. Generic substitution for brand name antiepileptic drugs: A survey. Can J Neurol Sci 27 (2000) 37-43
6. Wilner A.N. Therapeutic equivalency of generic antiepileptic drugs: Results of a survey. Epilepsy Behav 5 (2004) 995-998
7. Meyer M.C., and Straughn A.B. Biopharmaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm. 50 Suppl 5 (1993) S17-S22
8. MacDonald J.T. Breakthrough seizure following substitution of Depakene capsules (Abbott) with u generic product. Neurology 37 (1987) 1885
9. Wyllie E., Pippenger C.E., and Rothner A.D. Increased seizure frequency with generic primidone. JAMA 258 (1987) 1216-1217
10. Welty T.E., Pickering P.R., Hale B.C., and Arazi R. Loss of seizure control associated with generic substitution of carbazepine. Ann Pharmacother. 26 (1992) 775-777
11. Tyrer J.H., Eadie P.R., Sutherland J.M., and Hooper W.D. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 4 (1970) 271-273
12. Koch G., and Allen J.P. Untoward effects of generic carbamazepine therapy. Arch Neurol. 44 (1987) 578-579
13. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefiz (ODB) [Ontario Ministry of Health and Long-Term[are Web site] (2007-2007). http://www.health.gov.on.ca/english/public/program/drugs/drugs_mn.html
14. Canadian Adverse Drug Reaction Monitoring program ([ADRK4P). [ADRK4P Adverse Reaction Database Caveats regarding use of CADRMP data are listed onthe Web site (2007-January 2007). sc.gc.ca/dhp
15. Canadian Pharmacists Association. 2006 Compendium of Pharmaceuticals and Specialties. 41st ed. (2006), Canadian pharmacists Association, Ottawa, Ontario, Canada